Randomized study of thalidomide combined with vinorelbine and cisplatin chemotherapy for the treatment of advanced non-small cell lung cancer / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 298-301, 2009.
Article
in Chinese
| WPRIM
| ID: wpr-293127
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy, median time to progression (TTP), quality of life and toxicity in the patients with advanced non-small cell lung cancer (NSCLC), treated with thalidomide plus vinorelbine and cisplatin (NP) or NP alone.</p><p><b>METHODS</b>Sixty six patients with advanced NSCLC were divided randomly into two groups, the trial and control groups. The trial group was treated with vinorelbine 25 approximately 30 mg/m(2) i.v. on D1 and D8, cisplatin 70 approximately 80 mg/m(2) i.v. on D1 (NP regimen), and thalidomide 200 mg orally and daily from D1. The control group received vinorelbine and cisplatin as above described.</p><p><b>RESULTS</b>Of 66 assessable patients, the overall response rate was 51.5% in the trial group and 36.4% in the control group (P = 0.22). The median TTP was 6.0 months for the trial group, and 3.6 months for the control group (P < 0.001). The score of quality of life in trial group was higher than that in the control group, but no significant difference was observed between the two groups (P > 0.05). There were no significant differences in toxicities between the two groups (P > 0.05).</p><p><b>CONCLUSION</b>NP regimen combined with thalidomide can significantly prolong the median time to tumor progression in patients with advanced NSCLC. Thalidomide may have a synergic activity with NP regimen without increased toxicities.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Quality of Life
/
Thalidomide
/
Thrombocytopenia
/
Vinblastine
/
Vomiting
/
Remission Induction
/
Antineoplastic Combined Chemotherapy Protocols
/
Feeding and Eating Disorders
/
Follow-Up Studies
Type of study:
Controlled clinical trial
/
Observational study
/
Prognostic study
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Oncology
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS